Adipose-derived regenerative cells for treating liver injury
View Patent ↗Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.
1. A method of treating alcohol-induced liver injury in a patient in need thereof, comprising:
(a) identifying a patient with alcohol-induced liver injury;
(b) providing a tissue removal system;
(c) removing adipose tissue from a patient using the tissue removal system;
(d) processing at least part of the adipose tissue to obtain a concentrated population of adipose-derived cells comprising stem cells, wherein the concentration of stem cells is at least 0.1% of the adipose-derived cell population, wherein the processing comprises
disaggregating the adipose tissue to free adipocytes and other cell populations from adipose tissue matrix to obtain a cell suspension;
reducing the presence of free adipocytes in the cell suspension; and
concentrating the cell suspension, to obtain the concentrated population of adipose-derived cells comprising stem cells; and
(e) administering the concentrated population of adipose-derived cells comprising stem cells to the patient with alcohol-induced liver injury.
2. The method of claim 1 , wherein the liver injury is alcohol-induced liver injury.
3. The method of claim 1 , wherein the concentrated population of adipose-derived cells comprising stem cells is administered to the patient intravenously.
4. The method of claim 1 , wherein the concentrated population of adipose-derived cells comprising stem cells is administered to the patient through the hepatic circulatory system.
5. The method of claim 1 , wherein the concentrated population of adipose-derived cells comprising stem cells is cultured prior to administration to the patient.
6. The method of claim 1 , wherein the concentrated population of adipose-derived cells comprising stem cells is not cultured prior to administration to the patient.
7. The method of claim 1 , wherein the tissue removal system comprises:
a tissue collecting container configured to receive and fully or partially disaggregate adipose tissue, wherein said tissue collecting container is coupled to a cell collection container wherein said coupling defines a closed system in which said fully or partially disaggregated adipose tissue directed from tissue collecting container to cell collection container is not exposed to the external environment; and wherein said cell collection container, further comprises a cell concentrator that facilitates separation of the cells in a suspension; and
an outlet that is structured to permit said concentrated population of cells comprising adipose-derived cells to be removed from said adipose tissue processing unit.
8. The method of claim 1 , wherein the therapeutically effective amount of the concentrated population of adipose-derived regenerative cells comprises a minimum concentration of between 1×10 5 and 1×10 7 adipose-derived stem cells.
9. The method of claim 1 , wherein the concentrated population of cells comprising adipose-derived stem cells is processed to remove unwanted cell and tissue aggregates prior to administration.
10. The method of claim 1 , wherein the concentrated population of cells comprising adipose-derived stem cells comprises an additive.
11. The method of claim 10 , wherein the additive is selected from the group consisting of other cells, tissue, and tissue fragments.
12. The method of claim 10 , wherein the additive is selected from the group consisting of cytokines, growth factors and immunosuppressive agents.
13. The method of claim 1 , wherein the concentrated population of adipose-derived cells comprising stem cells is administered to the patient.
14. The method of claim 1 , wherein the stem cells comprise more than 0.1% of the cellular component of the concentrated population of adipose-derived cells.